659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC).

MLA

Martinez Chanza, N., et al. “659MO Avelumab (A) as the Basis of Neoadjuvant Chemotherapy (NAC) Regimen in Platinum Eligible and Ineligible Patients (Pts) with Non-Metastatic Muscle Invasive Bladder Cancer (NM-MIBC).” Annals of Oncology, vol. 32, Sept. 2021, p. S683. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.08.055.

APA

Martinez Chanza, N., Carnot, A., Barthelemy, P., Casert, V., Sautois, B., Van den Brande, J., Vanhaudenarde, V., Staudacher, L., Seront, E., Culine, S., Gizzi, M., Gil, T., Paesmans, M., Kotecki, N., Ignatiadis, M., Albisinni, S., Fantoni, J. C., Tricard, T., Roumeguere, T., & Awada, A. H. (2021). 659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC). Annals of Oncology, 32, S683. https://doi.org/10.1016/j.annonc.2021.08.055

Chicago

Martinez Chanza, N., A. Carnot, P. Barthelemy, V. Casert, B. Sautois, J. Van den Brande, V. Vanhaudenarde, et al. 2021. “659MO Avelumab (A) as the Basis of Neoadjuvant Chemotherapy (NAC) Regimen in Platinum Eligible and Ineligible Patients (Pts) with Non-Metastatic Muscle Invasive Bladder Cancer (NM-MIBC).” Annals of Oncology 32 (September): S683. doi:10.1016/j.annonc.2021.08.055.